New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

KARDIGAN INC

KARD

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

11.54 0.98 −7.83%

After hours trading: 11.54, unchanged, last trade Fri 4:01pm Eastern.

Market cap
$1.2B
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
−187.2%
Net debt / EBITDA
1.7×
Payout ratio
—

Where the cash went Q3 FY2026, quarter to Sep 30, 2026

Free cash flow was −$61.7M: capital expenditures were more than operating cash flow. Cash fell by $305.1M. What is a cash flow statement?

Free cash flow
−$61.7M
Returned to shareholders
$0.00
Debt, net
$0.00 borrowed
Change in cash
−$305.1M over the period
Where the cash went, in millions of dollars
Operating cash flow−59.9
Capital expenditures−1.8
Free cash flow−61.7
Into investments, net−238.5
Shares issued, net+0.2
Other−5.2
Change in cash−305.1
Operating cash flowCapexFree cash flow
Operating cash flow, capex and free cash flow, four quarters
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Operating cash flow−$52M−$57M−$51M−$60M
Capex−$1.2M−$2.6M−$2.3M−$1.8M
Free cash flow−$53M−$59M−$53M−$62M

Figures in millions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.

Older periods Dec '25 Mar '26 Jun '26 Sep '26
Net Income

+3 more quarters

(56.32) (56.07) (116.24) (58.57)
Operating Cash Flow
(51.71) (56.78) (50.55) (59.85)
Investing cash flow
(113.52) 19.01 (73.90) (241.87)
Financing cash flow
104.71 10.32 426.91 (3.39)
Ending Cash
(60.52) 82.09 302.46 (305.11)

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026